Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

JHOP Print Edition

JHOP Weekly e‑Newsletter

I have reviewed and consent to the terms of JHOP's Privacy Policy, and JHOP has my permission to retain my information in its database, and to forward pertinent communications to me.

2016 First Annual Oncology Guide to New FDA Approvals

Drug Profiles/Updates, FDA Updates

Imlygic (Talimogene Laherparepvec): First Oncolytic Viral Therapy for the Treatment of Patients with Recurrent Melanoma

Lisa A. Raedler, PhD, RPh, Medical Writer

Drug Profiles/Updates, FDA Updates

Imbruvica (Ibrutinib): First Drug Approved for the Treatment of Patients with Waldenström’s Macroglobulinemia

Lisa A. Raedler, PhD, RPh, Medical Writer

Drug Profiles/Updates, FDA Updates

Empliciti (Elotuzumab): First SLAMF7 Antibody Therapy Approved for the Treatment of Patients with Previously Treated Multiple Myeloma

Lisa A. Raedler, PhD, RPh, Medical Writer

Drug Profiles/Updates, FDA Updates

Darzalex (Daratumumab): First Anti-CD38 Monoclonal Antibody Approved for Patients with Relapsed Multiple Myeloma

Lisa A. Raedler, PhD, RPh, Medical Writer

Drug Profiles/Updates, FDA Updates

Bendeka (Bendamustine Hydrochloride): Rapid-Infusion Formulation Approved for Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphomas

Lisa A. Raedler, PhD, RPh, Medical Writer

Drug Profiles/Updates, FDA Updates

Alecensa (Alectinib), an Oral Tyrosine Kinase Inhibitor, Approved for Metastatic Non–Small-Cell Lung Cancer with ALK Mutation

Novel Pharmaceuticals, FDA Updates

FDA Approvals of Brand-Name Prescription Drugs in 2015

FDA Updates

Translation of Benchtop Science Arrives in Force, Improves Patient Care

Val R. Adams, PharmD, FCCP, BCOP

1
2

Page 2 of 2
Results 11 - 18 of 18

Copyright © Amplity Health. All rights reserved.